Lipoprotein Apheresis

Cardiology Clinics

Volumn 33, Issue 2, 2015, Pages 197-208

  Moriarty, Patrick M ^a   Hemphill, Linda ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; CVD; Familial hypercholesterolemia; LDL C; Lipoprotein apheresis; Lp(a)

Indexed keywords

CHOLESTEROL; DEXTRAN SULFATE; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPOPROTEIN;

ABDOMINAL DISCOMFORT; ADSORPTION; ANEMIA; APHERESIS; FAMILIAL HYPERCHOLESTEROLEMIA; FLOW KINETICS; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPOTENSION; LIPOPROTEIN APHERESIS; LIPOPROTEIN APHERESIS SYSTEM; PRECIPITATION; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; THORAX PAIN; TREATMENT CONTRAINDICATION; UNITED STATES; ATHEROSCLEROSIS; BLOOD; COMPLICATION; HYPERLIPOPROTEINEMIA TYPE II; PROCEDURES;

ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS;

EID: 84928786070     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2015.02.002     Document Type: Review

References (95)

1. de Gennes J.L., Touraine R., Maunand B., et al. Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. Bull Mem Soc Med Hop Paris 1967, 118(15):1377-1402.
2. Agishi T., Kaneko I., Hasuo Y., et al. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs 1980, 26:406-411.
3. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981, 2(8254):1005-1007.
4. Ito M.K., McGowan M.P., Moriarty P.M., et al. Management of familial hypercholesterolemias in adult patients: recommendations from the national lipid association expert panel on familial hypercholesterolemia. JClin Lipidol 2011, 5(3 Suppl):S38-45.
5. Vishwanath R., Hemphill L.C. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. JClin Lipidol 2014, 8:18-28.
6. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19(6):403-414.
7. Cohen J.D., Brinton E.A., Ito M.K., et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. JClin Lipidol 2012, 6(3):208-215.
8. Wieland H., Seidel D. Asimple specific method for precipitation of low density lipoproteins. JLipid Res 1983, 24(7):904-909.
9. Davidson W.S., Sparks D.L., Lund-Katz S., et al. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. JBiol Chem 1994, 269(12):8959-8965.
10. Susca M. Heparin-induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: technique and first clinical results. Ther Apher 2001, 5(5):387-393.
11. Mabuchi H., Michishita I., Takeda M., et al. Anew low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987, 68(1-2):19-25.
12. Schuff-Werner P. Clinical long-term results of H.E.L.P.-apheresis. ZKardiol 2003, 92(Suppl 3):III28-III29. [in German].
13. Gordon B.R., Kelsey S.F., Dau P.C., et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber study group. Am J Cardiol 1998, 81(4):407-411.
14. Bosch T., Gahr S., Belschner U., et al. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions. Ther Apher Dial 2006, 10(3):210-218.
15. Klingel R., Göhlen B., Schwarting A., et al. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial 2003, 7(3):359-364.
16. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-apheresis study group. Am J Cardiol 1998, 82(12):1489-1495.
17. Kroon A.A., van Asten W.N., Stalenhoef A.F. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996, 125(12):945-954.
18. Kroon A.A., Aengevaeren W.R., van der Werf T., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93(10):1826-1835.
19. Aengevaeren W.R., Kroon A.A., Stalenhoef A.F., et al. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-apheresis atherosclerosis regression study (LAARS). JAm Coll Cardiol 1996, 28(7):1696-1704.
20. Kroon A.A., van't Hof M.A., Demacker P.N., et al. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000, 152(2):519-526.
21. Marais A.D., Naoumova R.P., Firth J.C., et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. JLipid Res 1997, 38(10):2071-2078.
22. Pfohl M., Naoumova R.P., Klass C., et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. JLipid Res 1994, 35(11):1946-1955.
23. Holvoet P., Mertens A., Verhamme P., et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001, 21(5):844-848.
24. St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001, 104(19):2295-2299.
25. Napoli C., Ambrosio G., Scarpato N., et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997, 133(5):585-595.
26. Schamberger B.M., Geiss H.C., Ritter M.M., et al. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. JLipid Res 2000, 41(5):727-733.
27. Parhofer K.G., Barrett P.H., Demant T., et al. Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. JLipid Res 1996, 37(11):2383-2393.
28. Guerin M. Reverse cholesterol transport in familial hypercholesterolemia. Curr Opin Lipidol 2012, 23(4):377-385.
29. Richter W.O., Jacob B.G., Ritter M.M., et al. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993, 42(7):888-894.
30. Hershcovici T., Schechner V., Orlin J., et al. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. JClin Apher 2004, 19(2):90-97.
31. Schechner V., Berliner S., Shapira I., et al. Comparative analysis between dextran sulfate adsorption and direct adsorption of lipoproteins in their capability to reduce erythrocyte adhesiveness/aggregation in the peripheral blood. Ther Apher Dial 2004, 8(1):39-44.
32. Opole I.O., Belmont J.M., Kumar A., et al. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am J Cardiol 2007, 100(9):1416-1418.
33. Navab M., Ananthramaiah G.M., Reddy S.T., et al. The double jeopardy of HDL. Ann Med 2005, 37(3):173-178.
34. Matsuura F., Wang N., Chen W., et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. JClin Invest 2006, 116(5):1435-1442.
35. Orsoni A., Saheb S., Levels J.H., et al. LDL-apheresis depletes apoE-HDL and pre-beta1-HDL in familial hypercholesterolemia: relevance to atheroprotection. JLipid Res 2011, 52(12):2304-2313.
36. Moriarty P.M. Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. JClin Lipidol 2009, 4(3):311-329.
37. Schmaldienst S., Banyai S., Stulnig T.M., et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 2000, 151(2):493-499.
38. Mackey R.H., Greenland P., Goff D.C., et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-ethnic Study of Atherosclerosis). JAm Coll Cardiol 2012, 60(6):508-516.
39. Castillo S.M., Tye S., Moriarty P.M. Effect of lipid-apheresis on HDL-C functionality. Journal of American Cardiology 2013.
40. Richter W.O., Donner M.G., Schwandt P. Short- and long-term effects on serum lipoproteins by three different techniques of apheresis. Artif Organs 1996, 20(4):311-317.
41. Le N.A., Julie-Ann D., Moriarty P., et al. Acute changes in oxidative and inflammatory markers with LDL apheresis. Circulation 2006, 114:II-111. [abstract].
42. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. NEngl J Med 2009, 361(26):2518-2528.
43. Willeit P., Kiechl S., Kronenberg F., et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. JAm Coll Cardiol 2014, 64(9):851-860.
44. Leebmann J., Roeseler E., Julius U., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013, 128(24):2567-2576.
45. Jaeger B.R., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6(3):229-239.
46. Rosada A., Kassner U., Vogt A., et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein (a) levels reduce the incidence of cardiovascular events?. Artif Organs 2014, 38:135-141. [Erratum appears in Artif Organs 2014;38(2):177].
47. Geiss H.C., Bremer S., Barrett P.H., et al. Invivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis. JLipid Res 2004, 45(8):1459-1467.
48. Bosch T., Keller C. Clinical effects of direct adsorption of lipoprotein apheresis: beyond cholesterol reduction. Ther Apher Dial 2003, 7(3):341-344.
49. Nakamura T., Kawagoe Y., Ogawa H., et al. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis 2005, 45(1):48-53.
50. Ramunni A., Giancipoli G., Guerriero S., et al. LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy. Ther Apher Dial 2005, 9(1):53-58.
51. Bosch T., Schmidt B., Blumenstein M., et al. Lipid apheresis by hemoperfusion: invitro efficacy and exvivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993, 17(7):640-652.
52. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5):e69-171.
53. Stone P.H. Triggering myocardial infarction. NEngl J Med 2004, 351(17):1716-1718.
54. Grutzmacher P., Landgraf H., Esser R., et al. Invivo rheologic effects of lipid apheresis techniques: comparison of dextran sulfate LDL adsorption and heparin-induced LDL precipitation. ASAIO Trans 1990, 36:M327-M330.
55. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167(1):1-13.
56. Mii S., Mori A., Sakata H., et al. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Angiology 1998, 49(3):175-180.
57. Nakamura T., Ushiyama C., Osada S., et al. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. JDiabetes Complications 2003, 17(6):349-354.
58. Kojima S., Ogi M., Sugi T., et al. Changes in plasma levels of nitric oxide derivative during low-density lipoprotein apheresis. Ther Apher 1997, 1(4):356-361.
59. Kobayashi S., Moriya H., Negishi K., et al. LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. JClin Apher 2003, 18(3):115-119.
60. Schaumann D., Welch-Wichary M., Voss A., et al. Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 1996, 26(11):1033-1038. [see comment].
61. Wang Y., Blessing F., Walli A.K., et al. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175(1):145-150.
62. Julius U., Metzler W., Pietzsch J., et al. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002, 25(12):1180-1188.
63. Geiss H.C., Parhofer K.G., Donner M.G., et al. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher 1999, 3(3):199-202.
64. Blaha M. Adhesive selectin molecules MCP-1 and endothelin-1 during long-lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher 2005, 9(3):A29.
65. Spieker L.E., Ruschitzka F., Badimon J.J., et al. Shear stress-dependent platelet function after LDL cholesterol apheresis. Thromb Res 2004, 113(6):395-398.
66. Empen K., Otto C., Brödl U.C., et al. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. JClin Apher 2002, 17(1):38-43.
67. Palumbo B., Cardinali L., Sinzinger H. LDL-Apheresis removes serum amyloid P and A in hypercholesterolemic patients. Thromb Res 2000, 97(6):491-494.
68. Zanetti M., Zenti M., Barazzoni R., et al. HELP LDLapheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS One 2014, 9(7):e101290.
69. van Wijk D.F., Sjouke B., Figueroa A., et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol 2014, 64(14):1418-1426.
70. Angelkort B., Amann B., Lawall H. Hemorheology and hemostatis in vascular disease. A pathophysiological review. Clin Hemorheol Microcirc 2002, 26:145-154.
71. Moriarty P.M., Gibson C.A., Kensey K.R., et al. Effect of low-density lipoprotein cholesterol apheresis on blood viscosity. Am J Cardiol 2004, 93(8):1044-1046.
72. Rubba P., Iannuzzi A., Postiglione A., et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990, 81:610-616.
73. Schuff-Werner P., Schütz E., Seyde W.C., et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients beingtreated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989, 19(1):30-37.
74. Iannuzzi A., Bianciardi G., Faccenda F., et al. Correction of erythrocyte shape abnormalities in familial hypercholesterolemia after LDL-apheresis: does it influence cerebral hemodynamics?. Heart Vessels 1997, 12:234-240.
75. Alonso R., Andres E., Mata N., et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. JAm Coll Cardiol 2014, 63(19):1982-1989.
76. Tsuchida H., Shigematsu H., Ishimaru S., et al. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol 2006, 25(3):287-292.
77. Kobayashi S., Moriya H., Maesato K., et al. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. JClin Apher 2005, 20(4):239-243.
78. Takagi M., Yamada T., Yamaguchi H., et al. The role of low-density lipoprotein apheresis as postoperative care of bypass grafting for chronic arterial occlusion. Cardiovasc Surg 1996, 4(4):459-465.
79. Walzl B., Walzl M., Lechner P., et al. Heparin-induced extracorporeal LDL precipitation (HELP): a new therapeutic intervention in cerebrovascular diseases and peripheral arterial occlusive disease. Wien Med Wochenschr 1993, 143(22):563-570. [in Germany].
80. Hattori M., Chikamoto H., Akioka Y., et al. Acombined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003, 42(6):1121-1130.
81. Iwagami M., Negishi K. Kidney diseases. The concise manual of apheresis therapy 2014, 259-269. Springer, Tokyo, Japan. HN, E. Noiri (Eds.).
82. Muso E., Mune M., Fujii Y., et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001, 89(4):408-415.
83. Sosland R.P., Gollub S.B., Wilson D.B., et al. The first case report of the treatment of transplant coronary artery disease with dextran sulfate adsorption lipid apheresis. Ther Apher Dial 2010, 14(2):218-221.
84. Julius U., Tselmin S., Fischer S., et al. Lipid apheresis after heart transplantation - the Dresden experience. Tx Med 2010, 22:355-362.
85. Park J.W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. JHeart Lung Transplant 1997, 16(3):290-297.
86. Matschke K., Mrowietz C., Sternitzky R., et al. Effect of LDL apheresis on oxygen tension in skeletal muscle in patients with cardiac allograft vasculopathy and severe lipid disorder. Clin Hemorheol Microcirc 2004, 30(3-4):263-271.
87. Jaeger B.R., Meiser B., Nagel D., et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997, 96(9 Suppl):II-154-II-158.
88. Pfefferkorn T.K., Knüppel H.P., Jaeger B.R., et al. Increased cerebral CO(2) reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke 1999, 30(9):1802-1806.
89. Walzl M., Lechner H., Walzl B., et al. Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 1993, 24(10):1447-1451.
90. Moriarty P.M., Whittaker T.J. Treatment of acute occlusion of the retinal artery by LDL-apheresis. JClin Apher 2005, 20(2):88-92.
91. Pulido J.S., Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002, 100:85-106. [discussion: 106-7].
92. Ullrich H., Kleinjung T., Steffens T., et al. Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis. JClin Apher 2004, 19(2):71-78.
93. Balletshofer B.M., Stock J., Rittig K., et al. Acute effect of rheopheresis on peripheral endothelial dysfunction in patients suffering from sudden hearing loss. Ther Apher Dial 2005, 9(5):385-390.
94. Suckfull M., Hearing Loss Study Group Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 2002, 360(9348):1811-1817.
95. Wang Y., Walli A.K., Schulze A., et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci 2006, 35(2):103-110.